Xilio Therapeutics

Company snapshot

Xilio is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on defeating cancer. The company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its techn

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Xilio Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Xilio Therapeutics.

1. May 23, 2026 Clinical update

   XTX202 — Phase 2

2. May 23, 2026 Clinical update

   XTX301 — Phase 2

3. May 23, 2026 Clinical update

   vilastobart (XTX101) — Phase 2

4. Aug 12, 2025 Patent grant

   Activatable masked anti-CTLA4 binding proteins

5. Apr 22, 2025 Patent grant

   Tumor-specific cleavable linkers

View all clinical trial activity →

• What is Xilio Therapeutics?

  Xilio Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker XLO. Primary therapeutic focus areas include Advanced Solid Tumor. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 7 patent record(s) to this entity from p

• Is Xilio Therapeutics publicly traded?

  Yes. Xilio Therapeutics is listed with ticker XLO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Xilio Therapeutics develop or market?

  No drug profiles are currently linked to Xilio Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Xilio Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Xilio Therapeutics focus on?

  Xilio Therapeutics focuses on Advanced Solid Tumor based on our analysis of their pipeline programs and drug development activities.